Roles > SMO receptor antagonist
Page last updated: 2024-08-05 15:49:39
SMO receptor antagonist
An antagonist that interferes with the action of smoothened (SMO) receptor.
ChEBI ID: 66908
Members (3)
| Member | Definition | Class |
|---|
| gdc 0449 | A benzamide obtained by formal condensation between the carboxy group of 2-chloro-4-(methylsulfonyl)benzoic acid and the anilino group of 4-chloro-3-(pyridin-2-yl)aniline. Used for the treatment metastatic basal cell carcinoma. | vismodegib |
| glasdegib | A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a (2R,4S)-4-{[(4-cyanophenyl)carbamoyl]amino}-1-methylpiperidin-2-yl group at position 2. It is a hedgehog signalling pathway inhibitor that acts by binding to Smoothened (SMO) receptors and blocking signal transduction (IC50 = 5 nM). It is used in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients (aged >= 75 years), or who have medical conditions that prevent the use of standard chemotherapy. | glasdegib |
| lde225 | A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma. | sonidegib |
Research
Studies (794)
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (1.51) | 29.6817 |
| 2010's | 548 (69.02) | 24.3611 |
| 2020's | 234 (29.47) | 2.80 |
Study Types
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|
| Trials | 113 (12.65%) | 5.53% |
| Reviews | 168 (18.81%) | 6.00% |
| Case Studies | 133 (14.89%) | 4.05% |
| Observational | 6 (0.67%) | 0.25% |
| Other | 473 (52.97%) | 84.16% |
Protein Targets (19)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 9.3476 | 4 | 7 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 39.8107 | 1 | 1 |
Inhibition Measurements
Activation Measurements
Other Measurements